Monitor early combination trial data for signs of enhanced efficacy over monotherapy; assess whether responses in MTAPdel RASm tumors validate the dual-inhibition hypothesis. This collaboration de-risks Erasca’s development spend while expanding ERAS-0015’s clinical footprint.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $15.54entry
- T+1 · 9mo ago −0.45%α +0.86% · $15.47
- T+5 · 8mo ago −5.73%α −3.49% · $14.65
- T+20 · 8mo ago +14.61%α +18.40% · $17.81
- T+60 · 6mo ago −11.07%α −22.37% · $13.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate its pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat for treating MTAP-deleted RAS-mutant cancers. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the Phase 1/2 trial. The partnership targets a high unmet need in pancreatic and NSCLC cancers with a dual-pathway inhibition strategy.
Key Facts
- Erasca and Tango Therapeutics announced a clinical trial collaboration to evaluate ERAS-0015 (Erasca) + vopimetostat (Tango) in MTAP-deleted RAS-mutant pancreatic and NSCLC cancers.
- Tango will sponsor the Phase 1/2 trial; Erasca will supply ERAS-0015 at no cost.
- Each company retains full commercial rights; the agreement is non-exclusive.
- Preclinical data suggest ERAS-0015 has 5x greater RAS inhibition potency and up to 21x higher CypA binding affinity vs. RMC-6236.
- ERAS-0015 showed early clinical responses at 8 mg QD in multiple tumor types with different RAS mutations.
Financial Impact
No direct financial outlay from Erasca; potential long-term value creation if combination shows efficacy
Risk Factors
- Combination may not show synergistic efficacy despite strong preclinical rationale
- Safety concerns could emerge with dual pathway inhibition
- Unconfirmed partial responses in monotherapy may not mature into confirmed responses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250024 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers